Literature DB >> 22010043

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Aaron Boster1, Mary Pat Bartoszek, Colleen O'Connell, David Pitt, Michael Racke.   

Abstract

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

Entities:  

Keywords:  copaxone®; disease modifying therapies; glatiramer acetate; multiple sclerosis

Year:  2011        PMID： 22010043      PMCID： PMC3187678          DOI： 10.1177/1756285611422108

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


  76 in total

1.  Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid.

Authors:  Gregory P Owens; Alanna M Ritchie; Mark P Burgoon; R Anthony Williamson; John R Corboy; Donald H Gilden
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

2.  Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.

Authors:  David Azoulay; Veronika Vachapova; Boris Shihman; Ariel Miler; Arnon Karni
Journal:  J Neuroimmunol       Date:  2005-10       Impact factor: 3.478

Review 3.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

4.  Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

Authors:  Jason Ramtahal; Anu Jacob; Kumar Das; Mike Boggild
Journal:  J Neurol       Date:  2006-09-21       Impact factor: 4.849

5.  Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

Authors:  M Filippi; M Rovaris; M A Rocca; M P Sormani; J S Wolinsky; G Comi
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

6.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

7.  Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.

Authors:  Ralf A Linker; De-Hyung Lee; Seray Demir; Stefan Wiese; Niels Kruse; Ines Siglienti; Ellen Gerhardt; Harald Neumann; Michael Sendtner; Fred Lühder; Ralf Gold
Journal:  Brain       Date:  2010-08       Impact factor: 13.501

8.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

Authors:  Y Qin; P Duquette; Y Zhang; P Talbot; R Poole; J Antel
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

Review 10.  Multiple sclerosis: possible immunological mechanisms.

Authors:  H F McFarland; S Dhib-Jalbut
Journal:  Clin Immunol Immunopathol       Date:  1989-01
View more
  13 in total

Review 1.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 2.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

3.  Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.

Authors:  Antonietta Gentile; Silvia Rossi; Valeria Studer; Caterina Motta; Valentina De Chiara; Alessandra Musella; Helena Sepman; Diego Fresegna; Gabriele Musumeci; Giorgio Grasselli; Nabila Haji; Sagit Weiss; Liat Hayardeny; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-31       Impact factor: 4.147

Review 4.  The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.

Authors:  Benedikt Kretzschmar; Hannah Pellkofer; Martin S Weber
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 5.  Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.

Authors:  Guadalupe Marco-Martín; Pilar Tornero; Alicia Prieto; Alejandro La Rotta; Teresa Herrero; Maria Luisa Baeza
Journal:  Neurol Clin Pract       Date:  2020-04

6.  Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report.

Authors:  Attila Onmez; Ahmet Tarik Eminler; Hasan Ergenç; Meltem Baykara; Ihsan Uslan; Ali Tamer
Journal:  J Investig Med High Impact Case Rep       Date:  2013-12-17

Review 7.  Macrophage reprogramming for therapy.

Authors:  Valentina M T Bart; Robert J Pickering; Philip R Taylor; Natacha Ipseiz
Journal:  Immunology       Date:  2021-01-25       Impact factor: 7.215

Review 8.  Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.

Authors:  Matteo Caporro; Giulio Disanto; Claudio Gobbi; Chiara Zecca
Journal:  Patient Prefer Adherence       Date:  2014-08-21       Impact factor: 2.711

Review 9.  Teriflunomide and its mechanism of action in multiple sclerosis.

Authors:  Amit Bar-Or; Andrew Pachner; Francoise Menguy-Vacheron; Johanne Kaplan; Heinz Wiendl
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 10.  Risk evaluation and monitoring in multiple sclerosis therapeutics.

Authors:  Michel C Clanet; Jerry S Wolinsky; Raymond J Ashton; Hans-Peter Hartung; Stephen C Reingold
Journal:  Mult Scler       Date:  2013-11-30       Impact factor: 6.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.